Delving into the Latest Updates on Rubella vaccine, live-attenuated(Shanghai Institute of Biological Products) with Synapse

Overview

Basic Info

Drug Type

Live attenuated vaccine, Prophylactic vaccine

Synonyms

风疹减毒活疫苗(人二倍体细胞)(上海生物制品研究所)

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Other Diseases

Active Indication

Rubella

Inactive Indication-

Originator Organization

Shanghai Institute of Biological Products Co., Ltd.

Active Organization

Shanghai Institute of Biological Products Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

China (01 Jan 1998),

Rubella

Regulation-

Login to view timeline

Abstract In a family study of live, attenuated rubella-virus vaccine (HPV80), 85 susceptible placebo recipients were exposed to siblings with evidence of infection with the vaccine strain of rubella virus after inoculation. Of these placebo recipients a rise in titer of hemagglutination-inhibiting antibody developed in one. The type of antibody response and her clinical course indicated that vaccine virus infection had occurred. Although this response might have resulted from her having received vaccine by mistake, the possibility of intrafamilial spread of vaccine-strain virus must be seriously considered.

08 Aug 1968·New England Journal of MedicineQ1 · MEDICINE

Live, Attenuated Rubella-Virus Vaccine

Q1 · MEDICINE

Review

Author: Buynak, Eugene B. ; Weibel, Robert E. ; Hilleman, Maurice R. ; Stokes, Joseph

HIGH priority is being given in the United States and Europe to the development of an effective live, attenuated rubella (German-measles) virus vaccine. To be acceptable, a rubella vaccine should c...

100 Deals associated with Rubella vaccine, live-attenuated(Shanghai Institute of Biological Products)

Login to view more data